摘要
目的:探讨左乙拉西坦联合咪达唑仑在癫痫持续状态(SE)患者中的应用效果。方法:选取2020年5月—2023年9月宜春市人民医院收治的90例SE患者,按随机数字表法分为两组,各45例。对照组予以咪达唑仑治疗,观察组在对照组基础上加用左乙拉西坦治疗,随访3个月。比较两组治疗效果及安全性。结果:观察组总有效率较对照组高(P<0.05);治疗3个月后,观察组的操作智商(PIQ)、语言智商(VIQ)及总智商(FIQ)评分分别为(97.51±6.42)、(98.44±6.89)、(104.85±7.89)分,均高于对照组的(91.37±6.32)、(92.18±6.67)、(95.63±6.52)分,差异均有统计学意义(P<0.05);观察组治疗3个月后免疫球蛋白M(IgM)、免疫球蛋白A(IgA)水平分别为(1.32±0.24)、(1.78±0.28)g/L,均高于对照组的(1.13±0.22)、(1.45±0.26)g/L,差异均有统计学意义(P<0.05);观察组治疗3个月后白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、神经元特异性烯醇化酶(NSE)、高迁移率族蛋白B1(HMGB1)水平分别为(12.58±2.05)pg/mL、(16.29±2.18)μg/L、(49.36±5.17)μg/L、(3.42±0.41)ng/mL,均低于对照组的(14.87±2.12)pg/mL、(20.62±2.25)μg/L、(54.36±5.23)μg/L、(4.02±0.46)ng/mL,观察组的脑电图状态优于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:联用左乙拉西坦及咪达唑仑可增强SE患者疗效,纠正免疫球蛋白异常,降低血清IL-6、TNF-α、NSE、HMGB1水平,改善脑电图状态,安全可靠。
Objective:To investigate the effect of Levetiracetam combined with Midazolam in patients with status epilepticus(SE).Method:A total of 90 SE patients admitted to Yichun People's Hospital from May 2020 to September 2023 were selected and divided into two groups according to random number table method,with 45 cases in each group.The control group was treated with Midazolam,and the observation group was treated with Levetiracetam on the basis of the control group,the follow-up was 3 months.The therapeutic effect and safety of the two groups were compared.Result:The total effective rate of observation group was higher than that of control group(P<0.05).After 3 months of treatment,the performance IQ(PIQ),verbal IQ(VIQ)and full IQ(FIQ)scores of the observation group were(97.51±6.42),(98.44±6.89)and(104.85±7.89)scores,respectively,which were higher than(91.37±6.32),(92.18±6.67)and(95.63±6.52)scores in the control group,the differences were statistically significant(P<0.05).After 3 months of treatment,the levels of immunoglobulin M(IgM)and immunoglobulin A(IgA)in the observation group were(1.32±0.24)and(1.78±0.28)g/L,respectively,which were higher than(1.13±0.22)and(1.45±0.26)g/L in the control group,the differences were statistically significant(P<0.05).After 3 months of treatment,the levels of interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),neuron-specific enolase(NSE)and high mobility group protein B1(HMGB1)in the observation group were(12.58±2.05)pg/mL,(16.29±2.18)μg/L and(49.36±5.17)μg/L,(3.42±0.41)ng/mL,respectively,which were lower than(14.87±2.12)pg/mL,(20.62±2.25)μg/L,(54.36±5.23)μg/L,(4.02±0.46)ng/mL in the control group,the EEG state of the observation group was better than that of the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of Levetiracetam and Midazolam can enhance the efficacy of SE patients,correct the abnormality of immu
作者
漆苏
李晶
彭向玉
陈文碧
朱学鹏
袁俊
QI Su;LI Jing;PENG Xiangyu;CHEN Wenbi;ZHU Xuepeng;YUAN Jun(Neurology Department,Yichun People's Hospital,Yichun 336000,China;不详)
出处
《中国医学创新》
CAS
2024年第29期1-5,共5页
Medical Innovation of China
基金
江西省卫生健康委科技计划项目(202342220)。
